Related Experiment Video

Updated: Jun 2, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Target therapy in HER2-overexpressing breast cancer patients

Rosalba Amodio1, Maurizio Zarcone, Rosanna Cusimano

  • 1Palermo Province Cancer Registry, Department of Science for the Promotion of Health G.D. Alessandro, University of Palermo, Italy. amodiorosalba@libero.it

Omics : a Journal of Integrative Biology
|May 17, 2011
PubMed

Insights

High HER2 expression indicates a negative prognosis in early breast cancer. However, treatment with trastuzumab significantly improves overall survival for patients with HER2-overexpressing tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Research

Background:

  • HER2-targeted therapies, like monoclonal antibodies, offer new hope for early breast cancer.
  • HER2 overexpression is a critical factor in breast cancer progression and treatment response.

Purpose of the Study:

  • To evaluate the prognostic value of HER2 expression in early breast cancer.
  • To assess the impact of trastuzumab treatment on survival in HER2-positive patients.

Main Methods:

  • Retrospective analysis of 1401 non-metastatic invasive breast cancer cases from the Breast Cancer Registry of Palermo (2004-2006).
  • Correlation of HER2/neu oncogene expression with age, TNM staging, nodal involvement, and ER/PgR status.
  • Survival analysis comparing patients diagnosed in 2004 versus 2005-2006, with a focus on HER2 levels and trastuzumab treatment.

Main Results:

  • Nodal involvement, age, TNM, and receptor status were strong predictors of outcome in 2004.
  • HER2 expression levels significantly impacted overall survival in the 2004 cohort (p=0.001).
  • Patients with high HER2 expression treated with trastuzumab in 2005-2006 showed significantly improved survival compared to untreated patients (p=0.006).

Conclusions:

  • Elevated HER2 levels are a negative prognostic factor in early breast cancer.
  • Trastuzumab treatment significantly increases overall survival in HER2-overexpressing early breast cancer patients.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...